Nivolumab (NIVO) plus ipilimumab (IPI) versus chemotherapy (chemo) as first-line (1L) treatment for advanced non-small cell lung cancer (NSCLC): 4-year update from CheckMate 227.

被引：22
|
作者：
Paz-Ares, Luis G.
Ciuleanu, Tudor-Eliade
Lee, Jong-Seok
Urban, Laszlo
Caro, Reyes Bernabe
Park, Keunchil
Sakai, Hiroshi
Ohe, Yuichiro
Nishio, Makoto
Pluzanski, Adam
Ramalingam, Suresh S.
Brahmer, Julie R.
Borghaei, Hossein
O'Byrne, Kenneth John
Hellmann, Matthew D.
Memaj, Arteid
Bushong, Judith
Tran, Phuong
Reck, Martin
机构：
[1] Univ Complutense, CNIO H12o Lung Canc Clin Res Unit, Hosp Univ 12 Octubre, Madrid, Spain
[2] CiberOnc, Madrid, Spain
[3] Inst Oncol Prof Dr Ion Chiricuta, Cluj Napoca, Romania
[4] UMF Iuliu Hatieganu, Cluj Napoca, Romania
[5] Seoul Natl Univ, Bundang Hosp, Seongnam, South Korea
[6] Matrai Gyogyint, Matrahaza, Hungary
[7] Hosp Univ Virgen Del Rocio, Inst Biomed Seville, Seville, Spain
[8] Sungkyunkwan Univ, Sch Med, Samsung Med Ctr, Seoul, South Korea
[9] Saitama Canc Ctr, Saitama, Japan
[10] Natl Canc Ctr, Dept Thorac Oncol, Tokyo, Japan
[11] Japanese Fdn Canc Res, Canc Inst Hosp, Tokyo, Japan
[12] Maria Sklodowska Curie Natl Res Inst Oncol, Warsaw, Poland
[13] Emory Univ, Winship Canc Inst, Atlanta, GA 30322 USA
[14] Johns Hopkins Kimmel Canc Ctr, Baltimore, MD USA
[15] Fox Chase Canc Ctr, 7701 Burholme Ave, Philadelphia, PA 19111 USA
[16] Princess Alexandra Hosp, Brisbane, Qld, Australia
[17] Mem Sloan Kettering Canc Ctr, 1275 York Ave, New York, NY 10021 USA
[18] Bristol Myers Squibb, Princeton, NJ USA
[19] Bristol Myers Squibb, Springfield, PA USA
[20] German Ctr Lung Res, LungClin, Airway Res Ctr North, Grosshansdorf, Germany
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2021年 / 39卷 / 15期
关键词：
D O I：
10.1200/JCO.2021.39.15_suppl.9016
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
9016
引用
收藏
页数：4
相关论文
共 50 条
  • [31] CheckMate 012: Safety and efficacy of first-line (1L) nivolumab (nivo; N) and ipilimumab (ipi; I) in advanced (adv) NSCLC
    Hellmann, Matthew David
    Gettinger, Scott N.
    Goldman, Jonathan Wade
    Brahmer, Julie R.
    Borghaei, Hossein
    Chow, Laura Q.
    Ready, Neal
    Gerber, David E.
    Juergens, Rosalyn A.
    Shepherd, Frances A.
    Laurie, Scott Andrew
    Zhou, Ye
    Geese, William J.
    Agrawal, Shruti
    Li, Xuemei
    Antonia, Scott Joseph
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
  • [32] First-line nivolumab (NIVO) plus ipilimumab (IPI) vs chemotherapy (chemo) in patients (pts) with unresectable malignant pleural mesothelioma (uMPM): 4-year update from CheckMate 743
    Zalcman, G.
    Oulkhouir, Y.
    Cornelissen, R.
    Greillier, L.
    Cid, J. R. Rodriguez
    Mazieres, J.
    Briggs, P.
    Nowak, A. K.
    Tsao, A.
    Fujimoto, N.
    Peters, S.
    Mansfield, A. S.
    Popat, S.
    Nassar, A.
    Bushong, J.
    Hu, N.
    Spires, T.
    Balli, D.
    Eccles, L.
    Baas, P.
    ANNALS OF ONCOLOGY, 2022, 33 (07) : S1438 - S1439
  • [33] TUMOR GROWTH DYNAMIC (TGD) MODELING AND SAFETY ANALYSIS OF NIVOLUMAB (NIVO) PLUS IPILIMUMAB (IPI) IN FIRST-LINE (1L) PATIENTS (PTS) WITH NON-SMALL CELL LUNG CANCER (NSCLC).
    Zhao, X.
    Feng, Y.
    Wang, X.
    Young, T. C.
    Maier, S.
    Bello, A.
    Roy, A.
    Agrawal, S.
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2017, 101 (S1) : S53 - S53
  • [34] Nivolumab (NIVO) plus chemotherapy (Chemo) or ipilimumab (IPI) vs chemo as first-line (1L) treatment for advanced gastric cancer/gastroesophageal junction cancer/esophageal adenocarcinoma (GC/GEJC/EAC): CheckMate 649 study
    Janjigian, Y. Y.
    Ajani, J. A.
    Moehler, M.
    Garrido, M.
    Gallardo, C.
    Shen, L.
    Yamaguchi, K.
    Wyrwicz, L.
    Skoczylas, T.
    Bragagnoli, A.
    Liu, T.
    Tehfe, M.
    Elimova, E.
    Li, M.
    Poulart, V.
    Lei, M.
    Kondo, K.
    Shitara, K.
    ANNALS OF ONCOLOGY, 2021, 32 : S1329 - S1330
  • [35] Nivolumab (N) plus Low-Dose Ipilimumab (I) vs Platinum-Doublet Chemotherapy (Chemo) as First-Line (1L) Treatment (tx) for Advanced Non-Small Cell Lung Cancer (NSCLC): Checkmate 227 Part 1 Final Analysis
    Reck, Martin
    Peters, Solange
    Ramalingam, Suresh
    Paz-Ares, Luis
    Bernabe Caro, Reyes
    Zurawski, Bogdan
    Kim, Sang-We
    Alexandru, Aurelia
    Lupinacci, Lorena
    de la Mora Jitnenez, Emmanuel
    Sakai, Hiroshi
    Albert, Istvan
    Vergnenegre, Alain
    Borghaei, Hossein
    Brahmer, Julie R.
    O'byrne, Kenneth
    Geese, William J.
    Bhagavatheeswaran, Prabhu
    Nattan, Faith E.
    Hellmann, Matthew D.
    ONCOLOGY RESEARCH AND TREATMENT, 2020, 43 : 233 - 234
  • [36] Nivolumab (NIVO) Plus Low-Dose Ipilimumab (IPI) as First-Line (1L) Treatment (tx) of Advanced Nsclc: Overall Survival (Os) Analysis of Checkmate 817
    Fischer, Juergen R.
    Barlesi, Fabrice
    Audigier-Valette, Larisse
    Felip, Enriqueta
    Ciuleanu, Tudor-Eliade
    Jao, Kevin
    Rijavec, Erika
    Urban, Laszlo
    Aucoin, Jean-Sebastien
    Zannori, Cristina
    Vermaelen, Karim
    Aren Frontera, Osvaldo
    Ready, Neal
    Fontecedro, Alessandra Curioni
    Linardou, Helena
    Poddubskaya, Elena
    Pillai, Rathi
    Li, Sunney
    Acevedo, Angelic
    Paz-Ares, Luis
    ONCOLOGY RESEARCH AND TREATMENT, 2020, 43 : 236 - 236
  • [37] Treatment switching adjustment of overall survival in the CheckMate 227 clinical trial of nivolumab plus ipilimumab versus chemotherapy in first-line treatment of patients with advanced non-small cell lung cancer
    Reck, M.
    De, T.
    Paz-Ares, L.
    Yuan, Y.
    Chaudhary, A.
    Lee, A.
    Varol, N.
    Penrod, J.
    ANNALS OF ONCOLOGY, 2022, 33 (07) : S1024 - S1024
  • [38] Five-Year Survival Outcomes With Nivolumab Plus Ipilimumab Versus Chemotherapy as First-Line Treatment for Metastatic Non-Small-Cell Lung Cancer in CheckMate 227
    Brahmer, Julie R.
    Lee, Jong-Seok
    Ciuleanu, Tudor-Eliade
    Bernabe Caro, Reyes
    Nishio, Makoto
    Urban, Laszlo
    Audigier-Valette, Clarisse
    Lupinacci, Lorena
    Sangha, Randeep
    Pluzanski, Adam
    Burgers, Jacobus
    Mahave, Mauricio
    Ahmed, Samreen
    Schoenfeld, Adam J.
    Paz-Ares, Luis G.
    Reck, Martin
    Borghaei, Hossein
    O'Byrne, Kenneth J.
    Gupta, Ravi G.
    Bushong, Judith
    Li, Li
    Blum, Steven I.
    Eccles, Laura J.
    Ramalingam, Suresh S.
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (06) : 1200 - +
  • [39] Nivolumab (NIVO) plus chemotherapy (chemo) or ipilimumab (IPI) vs chemo as first-line (1L) treatment for advanced esophageal squamous cell carcinoma (ESCC): 29-month (mo) follow-up from CheckMate 648
    Greil, R.
    Kato, K.
    Ajani, J.
    Doki, Y.
    Xu, J.
    Wyrwicz, L.
    Motoyama, S.
    Ogata, T.
    Kawakami, H.
    Hsu, C. -H
    Adenis, A.
    El Hajbi, F.
    Di Bartolomeo, M.
    Braghiroli, M. Ignez
    Holtved, E.
    Murphy, M. Blum
    Patel, A.
    Hu, N.
    Matsumura, Y.
    Chau, I
    Kitagawa, Y.
    ONCOLOGY RESEARCH AND TREATMENT, 2023, 46 : 242 - 243
  • [40] Nivolumab (NIVO) plus chemotherapy (chemo) or ipilimumab (IPI) vs chemo as first-line (1L) treatment for advanced esophageal squamous cell carcinoma (ESCC): 45-month (mo) follow-up from CheckMate 648
    Chau, Ian
    Ajani, Jaffer A.
    Kitagawa, Yuko
    Xu, Jianming
    Wyrwicz, Lucjan S.
    Motoyama, Satoru
    Ogata, Takashi
    Kawakami, Hisato
    Hsu, Chih-Hung
    Adenis, Antoine
    El Hajbi, Farid
    Di Bartolomeo, Maria
    Braghiroli, Maria Ignez
    Holtved, Eva
    Murphy, Mariela A. Blum
    Nathani, Raheel
    Hu, Nan
    Matsumura, Yasuhiro
    Kato, Ken
    Doki, Yuichiro
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
12345